The company sources raw materials primarily through plasma collection centers and plasma fractionation facilities. Competitors in the plasma-derived protein therapeutics market include Grifols and CSL Behring, each operating more than 300 plasma collection centers in the United States. The company faces competition from emerging treatments such as antivirals, gene therapies, small molecules, correctors, monoclonal antibodies, and recombinant products. Sanofi acquired INBRX-101 from Inhibrx, a product in registrational trials for alpha-1 antitrypsin deficiency (AATD) treatment, now part of Sanofi's rare disease pipeline under the name efdoralprin alfa. Positive Phase 2 results for efdoralprin alfa may increase competition in the AATD market and affect demand for plasma-derived AAT products like GLASSIA. The company’s products generally lack patent protection and compete with similar products from other providers. Suppliers mentioned in filings include Aventis Inc., CSL Behring, Grifols, Inhibrx, and Sanofi.
Kamada Ltd's Comment on Supply Chain
The company sources raw materials primarily through plasma collection centers and plasma fractionation facilities. Competitors in the plasma-derived protein therapeutics market include Grifols and CSL Behring, each operating more than 300 plasma collection centers in the United States. The company faces competition from emerging treatments such as antivirals, gene therapies, small molecules, correctors, monoclonal antibodies, and recombinant products. Sanofi acquired INBRX-101 from Inhibrx, a product in registrational trials for alpha-1 antitrypsin deficiency (AATD) treatment, now part of Sanofi's rare disease pipeline under the name efdoralprin alfa. Positive Phase 2 results for efdoralprin alfa may increase competition in the AATD market and affect demand for plasma-derived AAT products like GLASSIA. The company’s products generally lack patent protection and compete with similar products from other providers. Suppliers mentioned in filings include Aventis Inc., CSL Behring, Grifols, Inhibrx, and Sanofi.
Sources:
Kamada Ltd 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Kamada Ltd ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
